JP2010523676A5 - - Google Patents

Download PDF

Info

Publication number
JP2010523676A5
JP2010523676A5 JP2010503070A JP2010503070A JP2010523676A5 JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5 JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010503070 A JP2010503070 A JP 2010503070A JP 2010523676 A5 JP2010523676 A5 JP 2010523676A5
Authority
JP
Japan
Prior art keywords
composition
liposome
peptide
hiv
immunogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010503070A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010523676A (ja
Filing date
Publication date
Priority claimed from US11/785,077 external-priority patent/US9402893B2/en
Priority claimed from US11/812,992 external-priority patent/US20080057075A1/en
Application filed filed Critical
Priority claimed from PCT/US2008/004709 external-priority patent/WO2008127651A1/en
Publication of JP2010523676A publication Critical patent/JP2010523676A/ja
Publication of JP2010523676A5 publication Critical patent/JP2010523676A5/ja
Pending legal-status Critical Current

Links

JP2010503070A 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法 Pending JP2010523676A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/785,077 US9402893B2 (en) 2005-04-12 2007-04-13 Liposome-peptide conjugate and method of using same to induce production of anti-HIV antibodies
US11/812,992 US20080057075A1 (en) 2005-04-12 2007-06-22 Method of inducing neutralizing antibodies to human immunodeficiency virus
US96041307P 2007-09-28 2007-09-28
PCT/US2008/004709 WO2008127651A1 (en) 2007-04-13 2008-04-11 Method of inducing neutralizing antibodies to human immunodeficiency virus

Publications (2)

Publication Number Publication Date
JP2010523676A JP2010523676A (ja) 2010-07-15
JP2010523676A5 true JP2010523676A5 (enExample) 2010-11-18

Family

ID=39864256

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010503070A Pending JP2010523676A (ja) 2007-04-13 2008-04-11 ヒト免疫不全ウイルスに対する中和抗体を誘導する方法

Country Status (6)

Country Link
US (2) US8956627B2 (enExample)
EP (1) EP2139516A4 (enExample)
JP (1) JP2010523676A (enExample)
AU (1) AU2008239628B2 (enExample)
CA (1) CA2683752A1 (enExample)
WO (1) WO2008127651A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235507B2 (en) 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US8956627B2 (en) 2007-04-13 2015-02-17 Duke University Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
JP2012502031A (ja) * 2008-09-05 2012-01-26 デューク ユニバーシティー 抗ウイルス免疫応答を誘導する方法
CA2757240A1 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies
WO2011046623A2 (en) * 2009-10-16 2011-04-21 Duke University Hiv-1 antibodies
AU2011219025A1 (en) * 2010-02-25 2012-09-27 Duke University Method of inducing the production of protective anti-HIV-1 antibodies
US20150359874A1 (en) * 2012-03-05 2015-12-17 Duke University Vaccine formulation
WO2015048635A1 (en) 2013-09-27 2015-04-02 Duke University Mper-liposome conjugates and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5916588A (en) * 1984-04-12 1999-06-29 The Liposome Company, Inc. Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use
US5831034A (en) * 1987-11-13 1998-11-03 Hermann Katinger Human monoclonal anti-HIV-I-antibodies
US4994440A (en) * 1989-02-13 1991-02-19 Creaven Patrick J Method for the treatment of renal cell carcinoma
EP0570357B1 (en) * 1992-05-14 1997-06-25 Polymun Scientific Immunbiologische Forschung GmbH Peptides that induce antibodies which neutralize genetically divergent HIV-1 isolates
AU678225B2 (en) * 1993-03-11 1997-05-22 University Of Southern California Therapeutic strategies for immunoinfective cluster virus infections
AU6989094A (en) * 1993-05-27 1994-12-20 Entremed, Inc Compositions and methods for treating cancer and hyperproliferative disorders
CA2168671C (en) 1993-08-06 2007-04-10 Yechezkel Barenholz A method for high loading of vesicles with biopolymeric substances
DE69426725T2 (de) 1993-09-11 2001-09-06 Polimun Scientific Immunbiologische Forschungsgesellschaft Mbh, Wien Peptide, die neutralisierende antikörper gegen genetisch divergierende hiv-1 stämme, induzieren
WO1995025124A1 (en) 1994-03-14 1995-09-21 University Of Southern California Methods to diagnose and treat hiv-1 infection
US6156337A (en) * 1994-07-08 2000-12-05 Opperbas Holding B.V. Method for high loading of vesicles with biopolymeric substances
US6207646B1 (en) * 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE219105T1 (de) 1995-04-19 2002-06-15 Polymun Scient Immunbio Forsch Monoklonale antikörper gegen hiv-1 und davon hergestellte impfstoffe
AU5978596A (en) * 1995-06-07 1996-12-30 U.S. Department Of The Army Liposomes containing human immunodeficiency virus glycoprote in and methods for use thereof
US5910306A (en) 1996-11-14 1999-06-08 The United States Of America As Represented By The Secretary Of The Army Transdermal delivery system for antigen
US5901306A (en) * 1997-06-23 1999-05-04 Sun Microsystems, Inc. Method and apparatus for reducing a computational result to the range boundaries of a signed 8-bit integer in case of overflow
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6300308B1 (en) * 1997-12-31 2001-10-09 Board Of Regents, The University Of Texas System Methods and compositions for inducing autoimmunity in the treatment of cancers
DE60215676T2 (de) 2001-09-07 2007-08-30 Polymun Scientific Immunbiologische Forschung Gmbh Gegen ein Peptid, das ein kryptisches Epitop von GP41 aus HIV-1 nachahmt gerichteter Körper
US7195768B2 (en) * 2001-11-07 2007-03-27 Duke University Polyvalent immunogen
JP4495969B2 (ja) * 2002-01-17 2010-07-07 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング Ｈｉｖ−１中和抗体を誘導する抗イディオタイプ抗体
US7611704B2 (en) * 2002-07-15 2009-11-03 Board Of Regents, The University Of Texas System Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7455833B2 (en) * 2002-07-15 2008-11-25 Board Of Regents, The University Of Texas System Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US20040131622A1 (en) * 2002-07-15 2004-07-08 Board Of Regents Combinations and kits for treating viral infections using immunoconjugates to aminophospholipids
US7384909B2 (en) * 2002-07-15 2008-06-10 Board Of Regents, The University Of Texas System Anti-viral treatment methods using phosphatidylethanolamine-binding peptides linked to anti-viral agents
US7572442B2 (en) 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Selected antibody compositions for binding to aminophospholipids
US7906115B2 (en) * 2002-07-15 2011-03-15 Thorpe Philip E Combinations kits and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipids
US7790159B2 (en) * 2002-07-15 2010-09-07 Board Of Regents, The University Of Texas System Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipids
US7678386B2 (en) * 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
EP1613643A4 (en) 2003-03-27 2009-10-28 Sudhir Paul LUPUS ANTIBODIES FOR THE PASSIVE IMMUNE THERAPY OF HIV / AIDS
US8147840B2 (en) * 2004-05-14 2012-04-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human immunodeficiency virus (HIV) immunization strategies employing conformationally-stabilized, surface-occluded peptides comprising a gp41 2F5 epitope in association with lipid
AU2006235507B2 (en) * 2005-04-12 2012-08-30 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
US20080057075A1 (en) * 2005-04-12 2008-03-06 Haynes Barton F Method of inducing neutralizing antibodies to human immunodeficiency virus
US8956627B2 (en) 2007-04-13 2015-02-17 Duke University Method of inducing antibodies to human immunodeficiency virus involving the administration of MPER peptide-liposome conjugates
KR101238795B1 (ko) * 2007-05-24 2013-03-07 글락소스미스클라인 바이오로지칼즈 에스.에이. 동결건조 항원 조성물
US20120070488A1 (en) * 2007-09-28 2012-03-22 Duke University Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2009111304A2 (en) 2008-02-29 2009-09-11 President And Fellows Of Harvard College A fusion-intermediate state of hiv-1 gp41 targeted by broadly neutralizing antibodies
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
AU2010232916A1 (en) 2009-04-03 2011-10-27 Children's Medical Center Corporation Formulation
CA2757240A1 (en) * 2009-04-03 2010-10-07 Duke University Formulation for inducing broadly reactive neutralizing anti-hiv antibodies

Similar Documents

Publication Publication Date Title
JP2018502885A5 (enExample)
Vaine et al. Antibody responses elicited through homologous or heterologous prime-boost DNA and protein vaccinations differ in functional activity and avidity
Pitisuttithum et al. Phase I/II study of a candidate vaccine designed against the B and E subtypes of HIV-1
JP2013181034A5 (enExample)
JP2007505033A5 (enExample)
WO2004009124A3 (en) Ghrelin-carrier conjugates
PE20071055A1 (es) Anticuerpos anti mn
WO2007099446A3 (en) Virosome-like vesicles comprising gp41-derived antigens
Fries et al. HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth
JP2013505201A5 (enExample)
NZ597458A (en) Hiv related peptides combination or fusion for use in hiv vaccine composition or as diagnostic means
OA09802A (en) Peptides for use in vaccination and induction of neutralizing antibodies against human immunodeficiency virus.
JP2010523676A (ja) ヒト免疫不全ウイルスに対する中和抗体を誘導する方法
JP2007513992A5 (enExample)
Agrawal et al. Generating neutralizing antibodies, Th1 response and MHC non restricted immunogenicity of HIV-I env and gag peptides in liposomes and ISCOMs with in-built adjuvanticity
WO2005111079A3 (en) Hiv vaccine immunogens and immunization strategies to elicit broadly-neutralizing anti-hiv-1 antibodies against the membrane proximal domain of hiv gp41
Xiao et al. Epitope-vaccine induces high levels of ELDKWA-epitope-specific neutralizing antibody
JP2006528650A5 (enExample)
ATE343592T1 (de) Gegen ein peptid, das ein kryptisches epitop von gp41 aus hiv-1 nachahmt gerichteter antikörper
Iglesias et al. Broader cross-reactivity after conjugation of V3 based multiple antigen peptides to HBsAg
RU2006129097A (ru) Новые тат-комплексы и включающие их вакцины
Kelker et al. A strategy for eliciting antibodies against cryptic, conserved, conformationally dependent epitopes of HIV envelope glycoprotein
KR20020080360A (ko) 특정의 교차 반응성을 증가시키는 항원성 구조들의 제조방법
Dong et al. ELNKWA-epitope specific antibodies induced by epitope-vaccine recognize ELDKWA-and other two neutralizing-resistant mutated epitopes on HIV-1 gp41
JP2007534615A5 (enExample)